Premium
Frameless stereotactic radiotherapy alone and combined with temozolomide for presumed canine gliomas
Author(s) -
Dolera M.,
Malfassi L.,
Bianchi C.,
Carrara N.,
Finesso S.,
Marcarini S.,
Mazza G.,
Pavesi S.,
Sala M.,
Urso G.
Publication year - 2018
Publication title -
veterinary and comparative oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.864
H-Index - 34
eISSN - 1476-5829
pISSN - 1476-5810
DOI - 10.1111/vco.12316
Subject(s) - temozolomide , medicine , radiation therapy , glioma , stereotactic radiotherapy , progressive disease , nuclear medicine , oncology , surgery , chemotherapy , radiosurgery , cancer research
We evaluated stereotactic volume modulated arc radiotherapy (VMAT) for canine gliomas, alone (radiotherapy [RT]) and in combination with temozolomide (RT + TMZ), compared with palliation. Overall and disease‐specific survival times were estimated. Thirty dogs were palliated, 22 dogs were treated with RT and 20 with RT + TMZ. Complete and partial responses were observed in 63.2% and 90.9% of patients in the RT and RT + TMZ arms, respectively, that were alive at 1 year. Median survival in the palliation arm was 94 days (95% conformity index [CI] 87÷101). Median survivals of the RT arm (383 days, 95% CI 276÷490) and RT+TMZ arm (420 days, 95% CI 280÷560) were not significantly different ( P = .61). Positive correlation with survival was found both for the ratio between target and brain (relative) volume of the tumour of <5% ( P = .013) and for a clinical presentation with normal mentation ( P = .032). VMAT is feasible and effective for canine brain gliomas. Combining this therapy with TMZ did not elicit any additional improvement in survival time.